| Drug General Information |
| Drug ID |
D02ZPV
|
| Former ID |
DNC006415
|
| Drug Name |
UCB-101333-3
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H26N4
|
| Canonical SMILES |
CC1=C(N=C(N=C1NC2CC2)C3CC3)N4CCCCCC4
|
| InChI |
1S/C17H26N4/c1-12-15(18-14-8-9-14)19-16(13-6-7-13)20-17(12)21-10-4-2-3-5-11-21/h13-14H,2-11H2,1H3,(H,18,19,20)
|
| InChIKey |
XMDRTFUFPOAGDR-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
CAMP-specific 3',5'-cyclic phosphodiesterase 4B |
Target Info |
Inhibitor |
[2]
|
|---|
| CAMP-specific 3',5'-cyclic phosphodiesterase 4A |
Target Info |
Inhibitor |
[2]
|
| Muscarinic acetylcholine receptor M3 |
Target Info |
Inhibitor |
[1]
|
| Type IV phosphodiesterase |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Purine metabolism
|
|
cAMP signaling pathway
|
|
Morphine addictionhsa00230:Purine metabolism
|
|
Morphine addictionhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Cholinergic synapse
|
|
Regulation of actin cytoskeleton
|
|
Insulin secretion
|
|
Salivary secretion
|
|
Gastric acid secretion
|
|
Pancreatic secretionhsa00230:Purine metabolism
|
|
Morphine addiction
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
PathWhiz Pathway
|
Gastric Acid ProductionPW000052:Purine Metabolism
|
|
Reactome
|
DARPP-32 events
|
|
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
|
|
G alpha (s) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
|
Acetylcholine regulates insulin secretion
|
|
G alpha (q) signalling eventsR-HSA-180024:DARPP-32 events
|
|
G alpha (s) signalling events
|
|
WikiPathways
|
G Protein Signaling Pathways
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Nuclear Receptors Meta-Pathway
|
|
Opioid SignallingWP35:G Protein Signaling PathwaysWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Regulation of Actin Cytoskeleton
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP35:G Protein Signaling Pathways
|
|
TSH signaling pathway
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80. Epub 2007 Mar 19.Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. |
|---|
| REF 2 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. Epub 2006 Jan 24.First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. |
|---|
